Diagnostic Performance of Diffusion-Weighted Imaging for Colorectal Cancer Detection: An Updated Systematic Review and Meta-Analysis

Yunfei Xiao¹, Juan Li¹, Jiamei Zhong¹, Dequan Chen², Jianbo Shi³ and Hongrui Jin¹*

¹ Department of Magnetic Resonance, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China,
² Department of Radiology, People’s Hospital of Chongqing Hechuan, Chongqing, China, ³ Department of Radiology, The Seventh People’s Hospital of Chongqing, Chongqing, China

Background: Magnetic resonance imaging (MRI), which uses strong magnetic fields and radio waves (radiofrequency energy) to make images, is one of the best imaging methods for soft tissues and can clearly display unique anatomical structures. Diffusion-weighted imaging (DWI) has been developed for identifying various malignant tumors.

Aim: To investigate the diagnostic value of DWI-MRI quantitative analysis in colorectal cancer detection.

Methods: The PubMed, Cochrane Library, and Embase databases were searched from inception to May 29, 2020. Studies published in English that used DWI-MRI for diagnosing colorectal cancer were included. Case reports, letters, reviews, and studies conducted in non-humans or in-vitro experiments were excluded. The pooled diagnostic odds ratio (DOR) and hierarchical summary receiver operating characteristic (HSROC) curves were computed for DWI, and the area under the curve (AUC) and associated standard error (SE) and 95% confidence intervals (CIs) were also used.

Results: In total, 15 studies with 1,655 participants were finally included in this meta-analysis. There were four prospective studies and 11 retrospective studies. Eight studies focused on rectal cancer, six on colorectal cancer, and one on colonic cancer. The performance of DWI-MRI for diagnosing colorectal cancer was accurate, with pooled sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of 0.88 (95% CI = 0.85–0.91), 0.92 (95% CI = 0.91–0.94), 30.36 (95% CI = 11.05–83.43), and 0.44 (95% CI = 0.30–0.64), respectively. The DOR and HSROC curves were 121 (95% CI = 56–261) and 0.92 (λ: 4.79), respectively.

Conclusion: DWI showed high diagnostic accuracy for colorectal cancer detection. Further studies with large sample sizes and prospective design are needed to confirm these results.

Keywords: colorectal cancer, diagnostic performance, DWI, MRI, sensitivity, meta-analysis
1 INTRODUCTION

Colorectal cancer is one of the most common types of cancer and the second leading cause of cancer-related mortality worldwide (1). The early diagnosis of colorectal cancer is crucial to prevent metastasis and reduce the fatality rate. Magnetic resonance imaging (MRI) is one of the best imaging methods for soft tissues and can clearly display unique anatomical structures. MRI can provide quantitative and qualitative information about the integrity of cell membranes and tissues. MRI can be used for initial diagnosis to determine the treatment plan for colorectal cancer (2). With the continuous development of MRI technology, the specificity and the diagnostic accuracy of traditional MRI for the detection of colorectal cancer have been largely improved (3).

Diffusion-weighted imaging (DWI) is a recently developed functional MRI imaging technique based on the movement of water molecules rather than the anatomical structure (4). Over the past decade, DWI has been widely used in the clinical setting for the early diagnosis of various cancers, such as breast cancer (4), prostatic cancer (5), and cervical cancer (6).

Several recent studies (7–10) have demonstrated that DWI provides high-contrast resolution morphological imaging, thereby significantly improving the diagnostic accuracy of colorectal cancer by MRI. In 2015, a meta-analysis (11) reported that DWI could be a highly accurate diagnostic method for the identification of colorectal cancer. However, previous meta-analyses included studies with small sample sizes published before May 2015, and stratified analyses could not be performed to draw a more detailed conclusion. Several recent studies with a larger sample size have provided new perspectives on this topic, and the reported DWI diagnostic performance was inconsistent with previous findings (12, 13). Given the recent evidence on the high accuracy of DWI in the preoperative diagnosis of colorectal cancer and the initial detection of colorectal neoplasms (14), an updated systematic review and meta-analysis was needed, which might provide specific suggestions for the early clinical diagnosis of colorectal cancer. Therefore, we conducted this meta-analysis to investigate the diagnostic performance of DWI-MRI for colorectal cancer detection.

2 MATERIALS AND METHODS

The current study was performed according to the guidelines of the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement (15).

2.1 Literature Search

The following individual and joint keywords “diffusion-weighted imaging,” “DWI,” “colorectal OR colon OR rectal OR CRC,” and “tumor OR cancer OR carcinoma OR neoplasm” were used for searching studies published in English in the PubMed, Cochrane Library, and Embase databases from inception to May 29, 2020. To identify additional relevant studies, the bibliographies of all relevant studies and reviews were manually searched, and Google Scholar was also searched for additional publications that cited relevant studies.

2.2 Eligibility Criteria

Studies were eligible for inclusion in this meta-analysis if they fulfilled the following criteria: 1) cases with a histologically confirmed diagnosis of colorectal cancer; 2) colorectal cancer detection or staging by DWI-MRI; 3) studies providing sufficient raw data to construct a $2 \times 2$ contingency table to perform MRI sequences; 4) studies published in English; and 5) for studies conducted using the same study participants, the most recent publication or the one with more detailed information was included.

Case reports, letters, reviews, studies conducted in non-humans or in-vitro experiments, studies not published in English, and studies for which data were not available were excluded from the analysis.

2.3 Data Extraction

All eligible studies were independently assessed by two reviewers. Any disagreement between them on study inclusion was resolved after consultation with a third reviewer. The data from the included studies were extracted using a standardized form, and consensus was reached on all items by the two reviewers. The following data were extracted: study characteristics (e.g., authors, year of publication, country, sample size, and study design), patient characteristics (e.g., mean age and female percentage), and imaging characteristics including field strength, type of coil, MR sequences and features, and the true-negative (TN), false-negative (FN), true-positive (TP), and false-positive (FP) values.

2.4 Methods of DWI-MRI Included

There are different methods in the field of DWI. In the current study, we assessed the diagnostic performance of DWI based on apparent diffusion coefficient (ADC) measurement, which relies on the ADC changing with the diffusion time as measurements move from restricted to free diffusion regimes.

2.5 Assessment of the Quality of Studies

The study quality was independently assessed and cross-checked by the two reviewers as per the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool (16). The QUADAS-2 comprises four domains: 1) patient selection, 2) index test, 3) reference standard, and 4) flow and timing.

2.6 Statistical Analysis

The sensitivity and specificity of DWI were calculated based on the TN, FN, TP, and FP values. The data from each study were pooled by using a random-effects model and expressed with the corresponding 95% confidence intervals (CI). The pooled diagnostic odds ratio (DOR) and hierarchical summary receiver operating characteristic (HSROC) curves were computed for DWI, and the area under the curve (AUC) and associated standard error (SE) and 95% CIs were also calculated. The DerSimonian and Laird random-effects method was
employed to determine the AUC of the SROC curves due to the presence of heterogeneity. The 95% CIs of the pooled metrics were compared to assess the relative diagnostic performance of the technique.

The $I^2$ statistics were used to assess the consistency of the effect sizes, which subsequently indicated the percentage of variability in effect estimates because of true interstudy variance rather than intrastudy variance. Heterogeneity was defined as low, moderate, and high by the $I^2$ values of 25%, 50%, and 75%, respectively (17). Publication bias was assessed by Begg’s rank correlation (18) and Egger’s weighted regression methods (19) ($p < 0.05$ indicated significant publication bias). Stata 15.0 (Stata Corporation, College Station, TX, USA) was used for the statistical analyses. The DOR and HSROCs were assessed with “metandi” modules in Stata software. A $p$-value <0.05 indicated a significant difference for all the analyses.

3 RESULTS

3.1 Study Selection

The search strategy yielded 611 potentially relevant studies, of which 209 were excluded due to overlapping data. Of the remaining 402 studies, 351 studies were excluded by browsing the titles or abstracts. Finally, 15 articles (7–10, 14, 20–28) were included for data extraction and meta-analysis after reading the full texts. The flowchart of the study selection process is shown in Figure 1.

3.2 Study Characteristics

In total, 15 studies with 1,655 participants were finally included in this meta-analysis. The characteristics of the included studies and participants are listed in Tables 1, 2. The studies were published between 2006 and 2020. Four studies were conducted in Turkey (8, 24–26); two each in China (7, 29), Japan (14, 22), France (10, 23), and Netherlands (9, 13); and one each in Italy (20), Germany (27) and India (21). Four studies were prospective, and the diagnoses of the all cases were confirmed by histopathological examination. Eight studies focused on rectal cancer, six on colorectal cancer, and one on coloncancer. Majority of the studies involved phased-array body coil and all studies used 1.5-T MRI. Two studies (24, 29) provided the results from one radiologist and the other studies involved two or three independent radiologists.

3.3 Assessment of Study Quality and Risk of Bias

The two reviewers independently evaluated each included study according to the QUADAS-2 items. None of the items of the QUADAS-2 was judged as high risk. The quality assessment results are presented in Supplementary Figure 1.

3.4 Diagnostic Accuracy

The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and HSROC for the diagnostic accuracy of DWI are presented in Figures 2–7, respectively. The DWI exam showed high diagnostic accuracy for colorectal cancer, with a sensitivity of 0.88 (95% CI = 0.85–0.91), a specificity of 0.92 (95% CI = 0.91–0.94), a PLR of 30.36 (95% CI = 11.05–83.43), and an NLR of 0.44 (95% CI = 0.30–0.64). The pooled DOR (121, 95% CI = 56–261) and HSROC (0.92, $\lambda = 4.79$) were consistent with the predicted results for sensitivity, specificity, PLR, and NLR. The forest plots suggested that heterogeneity was high, with almost all $I^2$ values >8%.

3.5 Subgroup Analysis

In Table 3, we presented the results on subgroups to explore the effect of study design and geographical regions for sampling on pooled sensitivity, specificity, PLR, NLR, and DOR. Five studies reported data on participants from Asian countries, and four were prospective studies. The pooled results for the studies grouped by study design showed no significant change when compared to the results of all the other studies. As the studies were categorized by country, the results for studies from non-Asian countries showed slightly better pooled sensitivity, specificity, PLR, and NLR. As shown in Table 3, by dividing the studies into various groups, the heterogeneity for sensitivity, specificity, PLR, NLR, and DOR was decreased to a moderate level ($I^2 < 75\%$). Moreover, we conducted a subgroup analysis with the inclusion of papers published after 2015, and the results are comparable with the results from all studies (Supplementary Figure 2).

3.6 Publication Bias

No potential publication bias was observed among the included trials (all $p$-values > 0.05) according to Begg’s rank correlation analysis and Egger’s weighted regression analysis. The detailed potential publication bias is presented in Supplementary Table 1.

4 DISCUSSION

The current study systemically explored the diagnostic accuracy of DWI in detecting colorectal cancer. Four prospective and 11
TABLE 1 | Characteristics of the studies.

| Studies included | Country | Cases | Control | Location of cancer | MRI | Case diagnosis method | Control | Study design |
|------------------|---------|-------|---------|-------------------|-----|-----------------------|---------|-------------|
| (14)             | Japan   | 64/31–81 | 11/4 | 65/51–81 | CR | Siemens AG | Histopathology | Other cancer cases | Prospective |
| (22)             | Japan   | 59/33–69 | 18/15 | NA | Siemens Healthcare | Histopathology | Colonoscopy-negative patients | Retrospective |
| (7)              | China   | 61/21–86 | 23/22 | NA | Siemens AG | Histopathology | Colonoscopy-negative patients | Prospective |
| (8)              | Turkey  | 57/NA | NA | 45/NA | CR | Siemens Healthcare | Histopathology | Colonoscopy-negative patients | Retrospective |
| (23)             | France  | 69/43–84 | 14/17 | 65/30–81 | CR | Siemens | Histopathology | Without recurrence cases | Prospective |
| (9)              | Netherlands | 68/35–87 | 13/10 | 64/22–81 | CR | GE Healthcare | Histopathology | Without recurrence cases | Retrospective |
| (24)             | Turkey  | 57/31–77 | 32/0 | NA | Siemens Healthcare | Histopathology | Healthy subjects | Retrospective |
| (25)             | Turkey  | 63/30–81 | 12/5 | 61/46–69 | CR | Siemens Magneton | Histopathology | Without recurrence cases | Prospective |
| (26)             | Turkey  | NA | NA | NA | CR | Siemens Magneton | Histopathology | Benign cases | Retrospective |
| (10)             | France  | 64/NA | 17/10 | 69/NA | R | Philips Medical | Histopathology | IBD cases | Retrospective |
| (27)             | Germany | 63/29–87 | 57/15 | NA | Siemens | Histopathology | Scar tissue | Retrospective |
| (13)             | Netherlands | 65/32–84 | NA | NA | Siemens Healthcare | Histopathology | Without recurrence cases | Retrospective |
| (20)             | Italy   | 64 | 12/6 | 63.76 | R | Siemens Magneton | Histopathology | Fibrosis | Retrospective |
| (29)             | China   | NA | NA | 27–67 | NA | Siemens Healthcare | Histopathology | Para-carcinoma tissue | Retrospective |
| (21)             | India   | 47/22–70 | 26/11 | 48/19–86 | CR | Siemens | Histopathology | Colonoscopy-negative patients | Retrospective |

MRI, magnetic resonance imaging; M, male; F, female; CR, colorectal; R, rectal; C, colonic; IBD, inflammatory bowel disease; NA, not available.

*Mean range, years.

retrospective studies were included in this meta-analysis. DWI showed good diagnostic ability for colorectal cancer detection, with pooled sensitivity, specificity, PLR, and NLR of 0.88 (95% CI = 0.85–0.91), 0.92 (95% CI = 0.91–0.94), 30.36 (95% CI = 11.05–83.43), and 0.44 (95% CI = 0.30–0.64), respectively, and the pooled area under the SROC curve was 0.9654. When the studies were categorized by country, the studies from non-Asian countries showed slightly higher diagnostic power.

TABLE 2 | Characteristics of magnetic resonance imaging.

| Studies included | Cases/controls | No. of readers | Coil type | Magnetic Methods | ADC value (mm²/s) | β value | Method of analysis |
|------------------|----------------|----------------|-----------|------------------|------------------|---------|-------------------|
| (14)             | 15/20          | 2              | Body and spine matrix coil | 1.5 T HSI, ADC | 1.19 1.37 | 0–500–1,000 | Visual |
| (22)             | 31/31          | 2              | Anterior torso phased-array coil | 1.5 T HSI, ADC | NA NA | 0–1,000 | Visual |
| (7)              | 33/15          | 3              | Phased-array body coil | 1.5 T ADC | NA NA | 0–500–1,000 | Visual |
| (8)              | 45/20          | 2              | Abdominal phased-array coil | 1.5 T ADC | 1.07 1.91 | 0–800 | Visual |
| (23)             | 42/22          | 3              | Phased-array body coil | 1.5 T ADC | 1.04 1.39 | 0–1,000 | Non-visual |
| (9)              | 19/23          | 2              | Phased-array body coil | 1.5 T ADC | 0.97 1.37 | 0–500–1,000 | Non-visual |
| (24)             | 23/30          | 1              | Phased-array body coil | 1.5 T ADC | 1.02 1.53 | 0–800 | Non-visual |
| (26)             | 26/15          | 2              | Phased-array body coil | 1.5 T HSI, ADC | 1.19 2.69 | 0–800 | Visual |
| (10)             | 27/31          | 2              | Phased-array body coil | 1.5 T HSI | NA NA | 0–800 | Visual |
| (27)             | 23/49          | 2              | Phased-array body coil | 1.5 T ADC | 1.02 1.77 | 0–100–400–800–1,000 | Non-visual |
| (13)             | 12/428         | 2              | Phased-array body coil | 1.5 T ADC | NA NA | 0–1,000 | Visual |
| (20)             | 18/25          | 3              | Phased-array body coil | 1.5 T ADC | 1.22 1.6 | 0–800 | Non-visual |
| (29)             | 186/165        | 1              | Phased-array body coil | 1.5 T ADC | NA NA | 0–800 | Visual |
| (21)             | 37/214         | 2              | Phased-array body coil | 1.5 T ADC | NA NA | 0–400–800 | Visual |

HSI, lesions were identified as malignant with the appearance of focal areas of high-signal intensity; ADC, lesions were identified as malignant with significantly lower ADC value; NA, not available.
Another meta-analysis (11) investigated DWI for colorectal cancer detection and showed a pooled sensitivity and specificity of 0.95 (95% CI = 0.90 – 0.97) and 0.93 (95% CI = 0.85 – 0.97), respectively. In the current study, five updated studies were counted, and in total, 15 studies were included. Compared with a previous meta-analysis, the five newly included studies had larger sample sizes, and finally, the number of study subjects was almost twice that of the previous one. We observed a similar diagnostic performance of DWI with the previous meta-analysis. Compared with the traditional MRI, DWI might obtain a better performance, and better diagnostic performance was also observed in other types of cancers, such as uterine cervical cancer (12), prostate cancer (30), and esophageal cancer (30). A study focused on cervical cancer (30) and the results demonstrated that the overall benefits of using DWI in 3.0-T MRI resulted in higher reader confidence, sensitivity of tissue infiltration, and tumor grading. Another meta-analysis (31) indicated that the diagnostic capacity of 1.5- and 3.0-T MRI scanners for prostatic cancer was comparable. In the current study, all patients were evaluated by 1.5-T MRI for colorectal cancer. In the future, a comparison of the diagnostic performance of 1.5- and 3.0-T MRI for colorectal cancer is needed. The recently developed functional MRI techniques provide high-contrast resolution morphological imaging, metabolic information, and direct depiction of tumor vascularity. The multiparametric MRI methods, such as DCE-MRI or combined DWI and DCE-MRI, might improve the sensitivity and specificity of detection and determination of tumor staging for colorectal cancer (32, 33).

One of the major aims of the colorectal cancer MRI test is to determine the tumor staging rather than tumor presence. This may be the reason that only a few studies have investigated DWI for the initial detection of colorectal cancer. In clinical settings, it is necessary to locate the tumor by MRI, and DWI may be helpful in the diagnosis of some particularly difficult cases, such as for smaller tumors or when the tumors are obscured by feces. Up to now, few studies have focused on the role of DWI in the staging of colorectal cancer. One study conducted by Lu et al. (34) reported that DWI was useful to evaluate the T stage of rectal cancer. Lymph node staging remains the most challenging task in clinical practice. Therefore, the implementation of DWI for lymph node staging is appealing. Since the value of DWI characterization for lymph nodes is still undefined (35), more applied clinical research on DWI is warranted in this area in the future.
The strengths of our study are the systemic search of potential studies in several popular databases and the high quality of the included studies. However, we need to consider the limitations of the present meta-analysis when interpreting the results. First, the studies included in the current meta-analysis were limited and the majority of them had small sample sizes. The small number of participants might reduce the credibility and stability of the results. Moreover, the small sample sizes also limited further subgroup analyses or sensitivity analyses, e.g., only a few studies on colon cancer were available, and MRI with DWI was reported to have a better performance in detecting more colonic cancers than CT (36). Second, some of the studies did not match the participants by age or gender. Therefore, the mean age and sex ratios of the participants among the included studies varied largely, which might also cause heterogeneity and reduce the stability of the results. Third, the included studies used varied controls, which might be one of the main reasons for the high heterogeneity. For the subgroup analysis, heterogeneity was decreased to a moderate level. Fourth, the technical factors for DWI might also affect the results of perfusion imaging. However, due to the limited number of the included studies, we could not conduct further analysis of the technical factors, such as the rate of contrast media injection and patients’ hemodynamic status. Fifth, due to insufficient data information, we could not report more results beyond tumor identification, such as detection of tumor margins. Sixth, although DWI might show diagnostic accuracy for colorectal cancer, in actual clinical practice, it might be affected by many factors, such as the varying experiences of the radiologists and the variations in image quality. This might be one obstacle in the implementation of DWI for the detection of colorectal cancer. Seventh, the effects of screening were likely

![FIGURE 6](image-url) | Summary of the pooled ROC plane.

![FIGURE 7](image-url) | Pooled hierarchical summary receiver operating characteristic (HSROC) curves.

| TABLE 3 | Subgroup analyses of the diagnostic performance of DWI. |
|---------|---------------------------------|
| Studies | No. of studies | Sensitivity (95% CI), I² | Specificity (95% CI), I² | PLR (95% CI), I² | NLR (95% CI), I² | Diagnostic OR (95% CI), I² |
|---------|----------------|--------------------------|--------------------------|-----------------|-----------------|--------------------------|
| All studies | 15 | 0.88 (0.85–0.91), 72.7% | 0.92 (0.91–0.94), 87.4% | 30.36 (11.05–83.43), 77.6% | 0.44 (0.30–0.64), 69.1% | 68.91 (21.09–225.13), 55.6% |
| Study design | | | | | | |
| Retrospective | 11 | 0.88 (0.84–0.91), 76.6% | 0.93 (0.91–0.94), 89.4% | 30.36 (11.05–83.43), 81.3% | 0.44 (0.30–0.64), 72.7% | 68.91 (21.09–225.13), 49.6% |
| Prospective | 4 | 0.89 (0.87–1.00), 64.2% | 0.91 (0.82–0.96), 81.3% | 14.34 (1.42–144.60), 79.4% | 0.15 (0.06–0.35), 63.5% | NA |
| Country | | | | | | |
| Asian | 5 | 0.84 (0.80–0.88), 82.8% | 0.88 (0.85–0.91), 93.2% | 8.29 (3.14–21.89), 82.5% | 0.20 (0.10–0.38), 82.4% | 40.54 (14.20–115.73), 65.8% |
| Others | 4 | 0.93 (0.89–0.96), 50.8% | 0.95 (0.93–0.97), 73.7% | 10.40 (5.93–18.27), 61.3% | 0.11 (0.07–0.19), 25.5% | 111.80 (57.72–216.56), 0.0% |

CI, confidence interval; PLR, positive likelihood ratio; NLR, negative likelihood ratio; OR, odds ratio; NA, not available.
to be overestimated results from publication bias, even though no publication bias was seen by both Begg’s and Egger’s tests. Finally, potential language bias might exist as our literature search included articles published in English only.

5 CONCLUSION
In summary, using DWI for the diagnosis of colorectal cancer might yield accurate AUC, sensitivity, and specificity. In the future, more studies addressing this topic with large sample sizes are warranted to confirm these results. The diagnostic performance of DWI for the detection of other cancers needs to be further evaluated and compared.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

REFERENCES
1. Pham TT, Talukder AM, Walsh NJ, Lawson AG, Jones AJ, Bishop JL, et al. Clinical and Epidemiological Factors Associated With Suicide in Colorectal Cancer. Supportive Care Cancer (2019) 27(2):617–21. doi: 10.1007/s00520-018-4354-3
2. Pech L, Cercueil JP, Jooste V, Krause D, Facy O, Bouvier AM. Current Use of MRI in Patients With Liver Metastatic Colorectal Cancer: A Population-Based Study. Eur J Gastroenterol Hepatol (2017) 29(10):1126–30. doi: 10.1097/meg.0000000000000933
3. Patterson DM, Padhani AR, Collins DJ. Technology Insight: Water Diffusion MRI—a Potential New Biomarker of Response to Cancer Therapy. Nat Clin Pract Oncol (2008) 5(4):220–33. doi: 10.1038/nccopn1073
4. Belli P, Buoi E, Buccheri C, Rinaldi P, Giuliani M, Romani M, et al. Role of DWI Assessing Nodal Involvement and Response to Neoadjuvant Chemotherapy in Advanced Breast Cancer. Eur Rev Med Pharmacol Sci (2017) 21(4):695–705.
5. Oto A, Kayhan A, Jiang Y, Tretiakova M, Yang C, Antic T, et al. Prostate Cancer: Differentiation of Central Gland Cancer From Benign Prostatic Hyperplasia by Using Diffusion-Weighted and Dynamic Contrast-Enhanced MR Imaging. Radiology (2010) 257(3):715–23. doi: 10.1148/radiol.1010021
6. Demirbas T, Cinilli S, Bayramoglu S, Guner NT, Hocaoglu E, Inci E. Contribution of Diffusion-Weighted Imaging to Diagnosis and Staging of Cervical Cancer. Balkan Med J (2014) 31(2):154–7. doi: 10.5152/balkanmedj.2014.13122
7. Rao SX, Zeng MS, Chen CZ, Li RC, Zhang SJ, Xu JM, et al. The Value of Diffusion-Weighted Imaging in Combination With T2-Weighted Imaging for Rectal Cancer Detection. Eur J Radiol (2008) 65(2):299–303. doi: 10.1016/j.ejrad.2007.04.001
8. Klickesmez O, Atilla S, Soylu A, Tasdelen N, Bayramoglu S, Cinilli T, et al. Diffusion-Weighted Imaging of the Rectosigmoid Colon: Preliminary Findings. J Comput Assist Tomogr (2009) 33(6):863–6. doi: 10.1097/RCT.0b013e31819a60f3
9. Lambrechts DM, Cappendijk VC, Maas M, Beets GL, Beets-Tan RG. Value of MRI and Diffusion-Weighted MRI for the Diagnosis of Locally Recurrent Rectal Cancer. Eur Radiol (2011) 21(6):1250–8. doi: 10.1007/s00330-010-2052-8
10. Colosio A, Soyer P, Rouset P, Barbe C, Nguyen F, Bouchez O, et al. Value of Diffusion-Weighted and Gadolinium-Enhanced MRI for the Diagnosis of Pelvic Recurrence From Colorectal Cancer. J Magn Reson Imaging (2014) 40(2):306–13. doi: 10.1002/jmri.24366
11. Jia H, Ma X, Zhao Y, Zhao J, Liu R, Chen Z, et al. Meta-Analysis of Diffusion-Weighted Magnetic Resonance Imaging in Identification of Colorectal Cancer. Int J Clin Exp Med (2015) 8(10):1733–42.
12. Exner M, Kuhn A, Stumpp P, Hockel M, Horn LC, Kahn T, et al. Value of Diffusion-Weighted MRI in Diagnosis of Uterine Cervical Cancer: A Prospective Study Evaluating the Benefits of DWI Compared to Conventional MR Sequences in a 3T Environment. Acta Radiol (2016) 57(7):869–77. doi: 10.1177/0284185115602146
13. Lambrechts DM, Lahaye MJ, Heijnen LA, Martens MH, Maas M, Beets GL, et al. MRI and Diffusion-Weighted MRI to Diagnose a Local Tumour Regrowth During Long-Term Follow-Up of Rectal Cancer Patients Treated With Organ Preservation After Chemoradiotherapy. Eur Radiol (2016) 26(7):2118–25. doi: 10.1007/s00330-015-4062-2
14. Hosonuma T, Tozaki M, Ichiba N, Sakuma T, Hayashi D, Yanaga K, et al. Clinical Usefulness of Diffusion-Weighted Imaging Using Low and High B-Values to Detect Rectal Cancer. Magn Reson Med Sci (2006) 5(4):173–7. doi: 10.2463/mrms.5.173
15. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med (2009) 6(7):e1000097. doi: 10.1371/journal.pmed.1000097
16. Whiting PF, Vessey ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of QUADAS, a Tool for the Quality Assessment of Diagnostic Accuracy Studies. BMC Med Res Method (2006) 6:9. doi: 10.1186/1471-2288-6-9
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring Inconsistency in Meta-Analyses. BMJ (Clin Res Ed) (2003) 327(7414):557–60. doi: 10.1136/bmj.327.7414.557
18. Begg CB, Mazumdar M. Operating Characteristics of a Rank Correlation Test for Publication Bias. Biometrics (1994) 50(4):1088–101. doi: 10.2307/2533446
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in Meta-Analysis Detected by a Simple, Graphical Test. BMJ (Clin Res Ed) (1997) 315(7109):629–34. doi: 10.1136/bmj.315.7109.629
20. Molinelli V, Angeretti MG, Duka E, Tarallo N, Bracchi E, Novario R, et al. Role of MRI and Added Value of Diffusion-Weighted and Gadolinium- Enhanced MRI for the Diagnosis of Local Recurrence From Rectal Cancer. Abdomin Radiol (New York) (2018) 43(11):2903–12. doi: 10.1007/s00138-018-1318-2
21. Chandramohan A, Siddiqui UM, Mittal R, Eapen A, Jesudason MR, Ram TS, et al. Diffusion Weighted Imaging Improves Diagnostic Ability of MRI for
31. Chen H, Sutedjo J, Wang L, Yin X. Prostate Cancer Magnetic Resonance Spectroscopy Imaging at 1.5 and 3.0 T: A Meta-Analysis. Technol Cancer Res Treat (2016) 15(4):625–31. doi: 10.1177/1533034616650779
32. Ahn SJ, An CS, Koom WS, Song HT, Sub JS. Correlations of 3T DCE-MRI Quantitative Parameters With Microvessel Density in a Human-Colorectal-Cancer Xenograft Mouse Model. Korean J Radiol (2011) 12(6):722–30. doi: 10.3348/klr.2011.12.6.722
33. Hirashima Y, Yamada Y, Tateishi U, Kato K, Miyake M, Horita Y, et al. Pharmacokinetic Parameters From 3-Tesla DCE-MRI as Surrogate Biomarkers of Antitumor Effects of Bevacizumab Plus FOLFIRI in Colorectal Cancer With Liver Metastasis. Int J Cancer (2012) 130(10):2359–65. doi: 10.1002/ijc.26282
34. Lu ZH, Hu CH, Qian WX, Cao WH. Preoperative Diffusion-Weighted Imaging Value of Rectal Cancer: Preoperative T Staging and Correlations With Histological T Stage. Clin Imaging (2016) 40(3):563–8. doi: 10.1016/j.clinimag.2015.12.006
35. Kim SH, Yoon JH, Lee Y. Added Value of Morphologic Characteristics on Diffusion-Weighted Images for Characterizing Lymph Nodes in Primary Rectal Cancer. Clin Imaging (2015) 39(6):1046–51. doi: 10.1016/j.clinimag.2015.07.022
36. Rafaelsen SR, Dam C, Vagn-Hansen C, Moller J, Rahr HB, Sjostrom M, et al. CT and 3 Tesla MRI in the TN Staging of Colon Cancer: A Prospective, Blind Study. Curr Oncol (2022) 29(2):1069–79. doi: 10.3390/cuoncol29020091

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, or the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xiao, Li, Zhong, Chen, Shi and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.